The ISM Services PMI unexpectedly fell to the breakeven point of 50, missing market forecasts and raising new questions about US economic momentum.
The regional banking giant has now cleared all regulatory hurdles for its pending all-stock transaction with Veritex Holdings, set to close in 2025.
ProSense cryoablation system gains marketing authorization as the first minimally invasive treatment for low-risk tumors in women over 70.
Zepzelca, in combination with Roche's Tecentriq, is the first approved first-line maintenance therapy for extensive-stage small cell lung cancer.
Regulators expedite review for ALTO-101, a novel treatment for cognitive impairment in schizophrenia, a condition with no currently approved therapies.
The newly formed company, which began trading on Nasdaq this week, faces intense volatility following the finalized deal and ahead of a planned reverse stock split.
Government award will advance the company's non-vaccine influenza therapeutic, CD388, and onshore its manufacturing ahead of a potential pandemic.
Regulators expedite review for ALTO-101, targeting a key aspect of schizophrenia with no currently approved treatments.